Trial Profile
A Randomized, Blinded, Prospective Study of the Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium-induced Neuromuscular Block in Obese Patients
Status:
Not yet recruiting
Phase of Trial:
Phase 0
Latest Information Update: 04 Oct 2019
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Atropine; Neostigmine
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 03 Nov 2017 New trial record